Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2019 - 2025)

Historic Long-Term Deferred Tax for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Q3 2025 value amounting to $103.1 million.

  • Vanda Pharmaceuticals' Long-Term Deferred Tax rose 2987.54% to $103.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.1 million, marking a year-over-year increase of 2987.54%. This contributed to the annual value of $81.4 million for FY2024, which is 858.67% up from last year.
  • Vanda Pharmaceuticals' Long-Term Deferred Tax amounted to $103.1 million in Q3 2025, which was up 2987.54% from $97.1 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Long-Term Deferred Tax peaked at $103.1 million during Q3 2025, and registered a low of $67.8 million during Q3 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Long-Term Deferred Tax had a median value of $75.3 million in 2024 and averaged $78.4 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 1189.35% in 2022, then surged by 2987.54% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Long-Term Deferred Tax stood at $74.9 million in 2021, then dropped by 1.12% to $74.0 million in 2022, then increased by 1.3% to $75.0 million in 2023, then grew by 8.59% to $81.4 million in 2024, then grew by 26.56% to $103.1 million in 2025.
  • Its Long-Term Deferred Tax stands at $103.1 million for Q3 2025, versus $97.1 million for Q2 2025 and $89.1 million for Q1 2025.